Hallux Valgus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hallux Valgus Market Outlook

Thelansis’s “Hallux Valgus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hallux Valgus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hallux Valgus Overview

Hallux valgus (HV), commonly known as a bunion, is a prevalent deformity affecting the forefoot. HV is characterized by lateral deviation of the proximal phalanx and medial deviation of the first metatarsal head, resulting from the adduction of the first metatarsus, known as metatarsus primus varus. The exact cause of HV is not fully understood, but it is likely the result of multiple contributing factors. These factors include genetics, a shortened first metatarsal, dorsiflexion (upward bending) of the first metatarsal, flexible or rigid varus deformity of the forefoot, flexible or rigid pes planovalgus (flatfoot), gastrocnemius equinus (tight calf muscles), abnormal foot mechanics, and joint hypermobility. HV deformity is commonly observed in individuals with connective tissue disorders such as Marfan syndrome, Ehlers-Danlos syndrome, and those with Down syndrome. The pathophysiology of HV is complex, involving an imbalance between the extrinsic and intrinsic muscles of the foot, along with the involvement of ligaments. The alignment of the first metatarsal is maintained through tension created by the peroneus longus muscle laterally and the abductor hallucis muscle medially. Other conditions to consider when evaluating patients with suspected HV deformity include osteoarthrosis, Freiberg disease, hallux rigidus, Morton neuroma, turf toe, gout, and septic joint. Physical examination is typically sufficient for diagnosing hallux valgus deformity, but imaging is important to assess potential damage to the first metatarsophalangeal (MTP) joint. Treatment options for HV deformity include both non-surgical and surgical approaches. The prognosis for HV deformity is generally favorable. Complications associated with HV deformity may include bursitis (most common), hammertoe deformity of the second toe, degenerative disease of the metatarsal head, central metatarsalgia, entrapment of the medial dorsal cutaneous nerve, and synovitis of the MTP joint. HV deformity is more prevalent in women than in men.

• The incidence of incident hallux valgus in adults aged 50 years or older is approximately 1 in 5 over seven years, and it is associated with age, poorer physical health, foot pain, and previous use of constrictive footwear.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: